StreetInsider.com News Articles

NexTel Medical expands acquisition to include Island 40 Group for $12.75M

Wed, 22 Jul 2026 12:16:45 -0400

NexTel Medical Corp. (OTCID: MAJI) has amended its previously announced acquisition of JumpstartRx and NuevistraMed to include Island 40 Group, the parent company of both entities, along with its full subsidiary platform, according to a press release.

Under the revised terms, NexTel will acquire Island 40 Group for total consideration of $12.75 million, comprising $3.5 million in cash and $9.25 million in preferred stock.

Island 40 Group's subsidiary platform includes JumpstartRx, a direct-to-consumer health and wellness platform; NuevistraMed, a pharmaceutical distribution and clinic support platform; Mascot Alliance, a partnership and revenue platform serving colleges, universities, and employers; ParkedIt Alliance, a motorsports business

NexTel Medical expands acquisition to include Island 40 Group for $12.75M

Wed, 22 Jul 2026 12:16:45 -0400

Under the revised terms, NexTel will acquire Island 40 Group for total consideration of $12.75 million, comprising $3.5 million in cash and $9.25 million in preferred stock.

NexTel Medical Corp. Amends Previously Announced Acquisition to Acquire Island 40 Group and Full Subsidiary Platform

Wed, 22 Jul 2026 12:16:00 -0400

Revised transaction expands NexTel’s acquisition from JumpstartRx and NuevistraMed to Island 40 Group’s broader growth platform, adding health services, pharmaceutical access, lab testing, institutional partnerships, and diversified revenue channels

ORLANDO, Fla., July 22, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI), a clinical-stage biotechnology company focused on proprietary exosome-based delivery systems, today announced that it has amended its previously announced acquisition of JumpstartRx and NuevistraMed to include the acquisition of Island 40 Group, the parent company of JumpstartRx and NuevistraMed, and its full subsidiary platform.

The revised transaction significantly expands the scope

NexTel Medical Corp. Amends Previously Announced Acquisition to Acquire Island 40 Group and Full Subsidiary Platform

Wed, 22 Jul 2026 12:16:00 -0400

The revised transaction significantly expands the scope

NexTel Medical Corp. Amends Previously Announced Acquisition to Acquire Island 40 Group and Full Subsidiary Platform

Wed, 22 Jul 2026 12:16:00 -0400

The revised transaction significantly expands the scope

NexTel Medical Corp. Amends Previously Announced Acquisition to Acquire Island 40 Group and Full Subsidiary Platform

Wed, 22 Jul 2026 12:16:00 -0400

The revised transaction significantly expands the scope

NexTel Medical Outlines its Revenue Model Using the Innovation of Tomorrow: Synergy of Advanced Medical Technologies and Massive Sales Infrastructure Primed to Drive Exponential Growth

Wed, 17 Jun 2026 07:00:00 -0400

BOCA RATON, Fla., June 17, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI) today announced a strategic pivot, evolutionary restructuring, and operational alignment designed to transition the company from a traditional development-stage biotech entity into a fully integrated, high-revenue healthcare platform. By seamlessly uniting its pioneering scientific innovations, recurring-revenue telehealth segments, and a massive, pre-existing patient distribution outlet, NexTel is positioning itself to rapidly commercialize next-generation medical solutions and maximize shareholder value.

At the center of this unified ecosystem are the company’s three primary operational drivers: Chairman of the Advisory Board Dr.

NexTel Medical Outlines its Revenue Model Using the Innovation of Tomorrow: Synergy of Advanced Medical Technologies and Massive Sales Infrastructure Primed to Drive Exponential Growth

Wed, 17 Jun 2026 07:00:00 -0400

At the center of this unified ecosystem are the company’s three primary operational drivers: Chairman of the Advisory Board Dr.

NexTel Medical Outlines its Revenue Model Using the Innovation of Tomorrow: Synergy of Advanced Medical Technologies and Massive Sales Infrastructure Primed to Drive Exponential Growth

Wed, 17 Jun 2026 07:00:00 -0400

At the center of this unified ecosystem are the company’s three primary operational drivers: Chairman of the Advisory Board Dr.

NexTel Medical Outlines its Revenue Model Using the Innovation of Tomorrow: Synergy of Advanced Medical Technologies and Massive Sales Infrastructure Primed to Drive Exponential Growth

Wed, 17 Jun 2026 07:00:00 -0400

At the center of this unified ecosystem are the company’s three primary operational drivers: Chairman of the Advisory Board Dr.

NexTel Medical Corp. Announces Groundbreaking, First-of-Its-Kind Exosome Characterization Study with Penn State University

Tue, 09 Jun 2026 07:00:00 -0400

Led by Scientific Advisory Board Members Dr. John Bitzer and Dr. Marvin Hausman, the Study Utilizes Advanced Mass Spectrometry to Identify the Precise Bioactive Healing Compounds Within Proprietary Mushroom Exosomes, Driving New Patent Filings and Product Pipelines.

ORLANDO, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems and integrated telehealth solutions, today announced a historic, first-of-its-kind analytical study in collaboration with Pennsylvania State University and esteemed Scientific Advisory Board (SAB) member, Dr. John Bitzer.